France · Funded startup

Who invested in Orakl Oncology

One round we have observed, with the 5 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Biotech

Funding summaryUpdated 26 Oct 2026

$1.0Mraised across 1 round since 2025, from 1 source

Latest round
Grant, $1.0MOct 2025
Investors
5
See who backed them

The rounds

  1. Oct 2025

Founders and team

From Orakl Oncology's own website: 3 founders, 5 on the team.

Fanny JaulinPhD, CEO and co-founder
Diane-Laure PagèsPhD, COO and co-founder
Gustave RonteixPhD, CTO and co-founder
  • Thibaud CaspariChief of staff
  • Mathieu RaulHead of Partnerships
  • Benoît Linsey FaziData engineer
  • Jean BouteillerLead Data scientist
  • Jerôme CaronPhD, Lab Director

Everyone who backed them

BpifranceGovernment1round
SpeedinvestVC firm1round
Verve VenturesVC firm1round
SingularVC firm1round
Amazon Web ServicesVC firm1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Orakl Oncology

Who invested in Orakl Oncology?

Orakl Oncology's investors include Bpifrance, Speedinvest, Verve Ventures, Singular and Amazon Web Services.

How much has Orakl Oncology raised?

Orakl Oncology has raised $1.0M across 1 round since 2025.

When did Orakl Oncology last raise?

Orakl Oncology's most recent round was a Grant of $1.0M in Oct 2025.

What was Orakl Oncology's biggest round?

Its most recent round, $1.0M in Oct 2025, is also its largest on record.

Who backed Orakl Oncology first?

Orakl Oncology's first round on record, in Oct 2025, was backed by Bpifrance, Speedinvest and Verve Ventures and 2 others.

What stage is Orakl Oncology at?

Orakl Oncology's latest named round is a Grant, in Oct 2025.

Where is Orakl Oncology based?

Orakl Oncology is based in France.

Companies like Orakl Oncology

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.